PALB2 and breast cancer: These results from a middle-income country health system lend further credence to an earlier analysis of the benefits of reductions in BC/OC cases and deaths from cost-effective unselected BRCA1/BRCA2/PALB2 multigene testing in high-income-country (USA/UK) health systems [9].